{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Response was assessed by the European Organization for Research and Treatment of Cancer (EORTC) modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response (CR) is complete disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) disease is at least a 20% increase in the sum of the LD of target lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.","groups":[{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.","id":"OG000","title":"Mesothelioma Pilot Phase Regimen A"},{"description":"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m\\^2 or 2 mg/m\\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\\^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m\\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\\^2 on days 1 and 5 of 25 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles.","id":"OG001","title":"Mesothelioma Pilot Phase Regimen"},{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.","id":"OG002","title":"Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase"},{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.","id":"OG003","title":"Phase 2 Pleural Mesothelioma Pilot Expansion Phase"},{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.","id":"OG004","title":"Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A"},{"description":"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\\^2 on day 1 of 21 day cycle\n\nOther Names:\n\n• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle\n\nOther Names:\n\n• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles.","id":"OG005","title":"Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No pts. were enrolled in the Phase 2 Lung Adenocarcinoma Pilot group.","reportingStatus":"POSTED","timeFrame":"52 months and 4 days","title":"Response Assessment","type":"PRIMARY","unitOfMeasure":"Participants"}